Enhanced release and drug delivery of celecoxib into physiological environment by the different types of nanoscale vehicles
Source abstract
Abstract
Abstract Celecoxib (CEL) as the very low water soluble drug was loaded 16 and 50% (w/w) through an impregnation method on varieties of alumina nanostructures such as synthetic sol-gel γ-alumina (Gam-Al), functionalized sol-gel γ-alumina (Gam-Al-NH 2 ), organized nano porous alumina (Onp-Al) and then the results compared with commercial alumina (Com-Al) and SBA-15 (SBA). Analyses of the samples were carried out by FT-IR, X-ray diffraction (XRD) and N 2 -sorption. in vitro studies were accomplished in simulated body fluid (SBF), simulated gastric fluid (SGF) and simulated intestinal fluid (SIF). In vivo study was carried out on male wistar rats under standard conditions. The N2-sorption revealed the initial pore characteristics of the nanocarriers. XRD patterns showed that the 50% loaded samples contain bulk celecoxib and its solubility in body fluids is lower than that of 16% loaded samples. In the case of 16% loaded samples, the drug solubility in three simulated body fluids drug was found to decrease in the following order: Gam-Al-CEL > Onp-Al-CEL > Com-Al-CEL > SBA-CEL. Gam-Al-CEL showed the highest release (96%) in SBF after 60 min in vivo study showed significant decrease in pain score in rats for Gam-Al-NH 2 -CEL-16% and Gam-Al-CEL-50%. It could be concluded that the synthetic aluminas have a developing future potential compared to the formal SBA and commercial alumina.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Neuropeptides and Animal Physiology · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib: PVP amorphous solid dispersions10.1016/j.ejpb.2016.02.007 ↗
2. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes10.1517/17425241003663236 ↗
3. Celecoxib for the treatment of atherosclerosis
4. Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx10.1016/j.ejps.2015.10.009 ↗
5. Enhancement of celecoxib solubility by solid disperson using mannitol
6. Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: drug loading and release properties10.1016/j.ijpharm.2010.07.040 ↗
7. Solid phospholipid dispersions for oral delivery of poorly soluble drugs: investigation into celecoxib incorporation and solubility- in vitro permeability enhancement
8. Functional nanoporous membranes for drug delivery10.1039/c2jm32430j ↗
9. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation10.1001/archinte.160.14.2093 ↗
10. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan10.1016/j.jconrel.2010.04.029 ↗
11. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility10.1039/c0jm03851b ↗
12. Use of porous aluminosilicate pellets for drug delivery10.1080/02652040500100196 ↗
13. Mesoporous materials as controlled drug delivery formulations10.1016/S1773-2247(11)50016-4 ↗
14. Studies on MCM-41 mesoporous silica for drug delivery: effect of particle morphology and amine functionalization10.1016/j.cej.2007.07.078 ↗
15. Mesoporous materials for drug delivery10.1002/anie.200604488 ↗
16. Porous materials: a tricontinuous mesoporous system10.1038/nchem.190 ↗
17. Continuous mesoporous silica films with highly ordered large pore structures10.1002/(SICI)1521-4095(199811)10:16<1380::AID-ADMA1380>3.0.CO;2-8 ↗
18. One-pot synthesis of 2-aminotetrahydrothiopyrano[4 3-b]pyran-3-carbonitrile derivatives using mesoporous NH2-MCM-4110.1007/s00706-013-1035-2 ↗
19. Immobilization of Keggin and Preyssler tungsten heteropolyacids on various functionalized silica10.1016/j.jcis.2006.07.024 ↗
20. Grafted chromium 13-membered dioxo-macrocyclic complex into aminopropyl-based nanoporous SBA-1510.1016/j.jssc.2013.04.027 ↗
21. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers10.1016/j.addr.2008.03.012 ↗
22. Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-Drug interactions10.1021/la051167e ↗
23. In fl uence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release10.1016/j.jconrel.2009.07.015 ↗
24. Synthesis, characterization and catalytic applications of organized mesoporous aluminas10.1080/01614940701804042 ↗
25. Generation of highly stable and active strong base sites on organized nano-porous alumina by calcium oxide10.1016/j.solidstatesciences.2012.11.010 ↗
26. Adsorption of Wells-Dawson tungsten heteropolyacid on sol-gel alumina: structural features and thermal stability10.1016/j.jcis.2005.05.090 ↗
27. Transition alumina phases induced by heat treatment of boehmite: an X-ray diffraction and infrared spectroscopy study10.1016/j.jssc.2009.02.006 ↗
28. A new nano-Platform for drug release via nanotubular aluminum oxide10.4236/jbnb.2011.23028 ↗
29. Borbane · 2015
30. Homogeneously dispersed ceria nanocatalyst stabilized with ordered mesoporous alumina10.1002/adma.200904223 ↗
31. Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release10.1016/j.jconrel.2009.07.015 ↗
32. Effects of surface acidity and pore size of mesoporous alumina on degree of loading and controlled release of ibuprofen10.1016/j.micromeso.2008.08.042 ↗
33. Mechanism of dissolution enhancement and bioavailability of poorly water soluble celecoxib by preparing stable amorphous nanoparticles10.18433/J3530J ↗
34. Solubility enhancement of celecoxib using beta-cyclodextrin inclusion complexes10.1016/j.ejpb.2003.10.020 ↗
35. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib10.1248/bpb.27.1993 ↗
36. Influence of polymers on the bioavailability of microencapsulated celecoxib10.1080/09637480701497360 ↗
37. Advantages of celecoxib nanosuspension formulation and transformation into tablets10.1016/j.ijpharm.2009.04.038 ↗
38. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers10.1016/j.jconrel.2010.02.006 ↗
39. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy10.1016/j.ejps.2012.01.003 ↗
40. Adsorption of Wells-Dawson tungsten heteropolyacid on sol-gel alumina: structural features and thermal stability10.1016/j.jcis.2005.05.090 ↗
41. Controllable release of ibuprofen from size-adjustable and surface hydrophobic mesoporous silica spheres10.1016/j.powtec.2008.09.001 ↗
42. Synthesis and characterization of mesoporous SBA-15/propranolol hydrochloride for controlled drug release study10.1007/s10971-012-2805-8 ↗
43. The formalin test: an evaluation of the method10.1016/0304-3959(92)90003-T ↗
44. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats10.1016/0304-3959(77)90130-0 ↗
45. Mediators of the inflammation induced in the rat paw by carrageenin10.1111/j.1476-5381.1971.tb07124.x ↗
46. Hydration of γ-Alumina in water and its effects on surface reactivity10.1021/la025651i ↗
47. Characterization of solid-state forms of celecoxib10.1016/S0928-0987(03)00201-X ↗